BDBM284770 US10023575, Example 61::US10023575, Example 90a::US10023575, Example 90b::US10479794, Example 90b::US10875867, Example 61::US11691977, Example 61

SMILES Cc1nn2cc(cnc2c1C(=O)NC1(CCOCC1O)c1ncc(cc1F)C(F)(F)F)C1CC1

InChI Key InChIKey=HHFHRXGILXOORN-UHFFFAOYSA-N

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 284770   

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 14nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 14nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2020
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 19nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2020
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 19nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 19nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 19nMAssay Description:Assay Principle: The PDE reaction cleaves cAMP to AMP. The IMAP system (Molecular Device) using fluorescence polarization (FP) as detection principle...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 200nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2020
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 200nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 6.65E+3nMAssay Description:Assay Principle: The PDE reaction cleaves cAMP to AMP. The IMAP system (Molecular Device) using fluorescence polarization (FP) as detection principle...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 6.65E+3nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 6.65E+3nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2020
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 6.65E+3nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 7.35E+3nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 7.35E+3nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2020
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 8.59E+3nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 8.59E+3nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2020
Entry Details
US Patent